Wong Brett J, Tublitz Nathan J, Minson Christopher T
Department of Human Physiology, University of Oregon, Eugene, OR, USA.
J Physiol. 2005 Nov 1;568(Pt 3):1047-56. doi: 10.1113/jphysiol.2005.095372. Epub 2005 Aug 25.
The neuropeptide substance P is known to be localized in nerve terminals in human skin and substance P-induced vasodilatation is believed to be partially dependent on nitric oxide (NO) and H1 histamine receptor activation. Unlike other neuropeptides investigated in human skin, substance P-induced vasodilatation has been shown to decline during continuous infusion, possibly suggestive of an internalization of neurokinin-1 (NK1) receptors, which are highly specific to substance P. However, questions remain regarding these mechanisms in human skin. Fifteen subjects participated in this series of studies designed to investigate the effect of consecutive infusions and possible mechanisms of substance P-induced vasodilatation in human skin. Two concentrations of substance P (10 microm and 20 microm) were tested via intradermal microdialysis in two groups of subjects. Site 1 served as a control and received substance P only. Site 2 received substance P combined with 10 mm L-NAME to inhibit NO synthase. Site 3 received substance P combined with 500 microm pyrilamine, an H1 receptor antagonist. Site 4 received substance P combined with 10 mm L-NAME plus 500 microm pyrilamine. Red blood cell (RBC) flux was measured via laser-Doppler flowmetry to provide an index of skin blood flow. Cutaneous vascular conductance was calculated as RBC flux/mean arterial pressure and was normalized to maximal vasodilatation via 28 mm sodium nitroprusside. Substance P was perfused through each microdialysis fibre at a rate of 4 microl min(-1) for 15 min. The subsequent increase in skin blood flow was allowed to return to baseline (approximately 45-60 min) and a stable 5 min plateau was used as a new baseline (post-infusion baseline). A second dose of substance P was then delivered to the skin and skin blood flow was monitored for 45-60 min. Substance P produced a dose-dependent increase in skin blood flow with the concentrations of substance P tested, which was significantly attenuated in the presence of L-NAME and the combination of L-NAME plus pyrilamine. However, substance P-induced vasodilatation was unaffected in the presence of pyrilamine. There was no significant difference between the L-NAME-only sites and the L-NAME plus pyrilamine sites. Importantly, the second dose of substance P did not produce a significant increase in skin blood flow compared to the initial baseline or the post-infusion baseline. These data suggest substance P-induced vasodilatation delivered via microdialysis contains an NO component but does not contain an H1 receptor activation component at the doses tested. Additionally, these data provide evidence for NK1 receptor desensitization as there was no observable increase in skin blood flow following a second administration of substance P. This may provide a useful model for studying the role of substance P in the control of skin blood flow in humans.
已知神经肽P物质定位于人类皮肤的神经末梢,并且P物质诱导的血管舒张被认为部分依赖于一氧化氮(NO)和H1组胺受体激活。与在人类皮肤中研究的其他神经肽不同,P物质诱导的血管舒张在持续输注过程中已显示出下降,这可能暗示神经激肽-1(NK1)受体的内化,该受体对P物质具有高度特异性。然而,关于人类皮肤中的这些机制仍存在疑问。15名受试者参与了这一系列研究,旨在研究连续输注的影响以及P物质诱导人类皮肤血管舒张的可能机制。通过皮内微透析在两组受试者中测试了两种浓度的P物质(10微摩尔和20微摩尔)。部位1作为对照,仅接受P物质。部位2接受P物质与10毫摩尔L-精氨酸甲酯(L-NAME)联合使用以抑制一氧化氮合酶。部位3接受P物质与500微摩尔吡咯胺(一种H1受体拮抗剂)联合使用。部位4接受P物质与10毫摩尔L-NAME加500微摩尔吡咯胺联合使用。通过激光多普勒血流仪测量红细胞(RBC)通量,以提供皮肤血流的指标。皮肤血管传导率计算为RBC通量/平均动脉压,并通过28毫米硝普钠将其标准化为最大血管舒张。以4微升/分钟的速率通过每个微透析纤维灌注P物质15分钟。随后允许皮肤血流的增加恢复到基线(约45 - 60分钟),并将稳定的5分钟平台期用作新的基线(输注后基线)。然后将第二剂P物质递送至皮肤,并监测皮肤血流45 - 60分钟。在所测试的P物质浓度下,P物质使皮肤血流呈剂量依赖性增加,在存在L-NAME以及L-NAME加吡咯胺的组合时,这种增加显著减弱。然而,在存在吡咯胺的情况下,P物质诱导的血管舒张未受影响。仅使用L-NAME的部位与使用L-NAME加吡咯胺的部位之间没有显著差异。重要的是,与初始基线或输注后基线相比,第二剂P物质未使皮肤血流产生显著增加。这些数据表明,通过微透析递送的P物质诱导的血管舒张包含一个NO成分,但在所测试的剂量下不包含H1受体激活成分。此外,这些数据为NK1受体脱敏提供了证据,因为在第二次给予P物质后未观察到皮肤血流增加。这可能为研究P物质在人类皮肤血流控制中的作用提供一个有用的模型。